Abiopharma

🔍 Wallace Willliam J IV (Executive)

Company: Origin Bancorp, Inc. (OBK)

Report Date: 2026-08-19

Detailed Transactions and Holdings:

• Acquired 2,226 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: M | equity_swap_involved: 0 | shares_owned_after: 19,639.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 593 shares of Common Stock at $52.51 per share (Direct)
  Date: 2026-08-19 | Code: F | equity_swap_involved: 0 | shares_owned_after: 19,046.00 | transaction_form_type: 4 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-08-19 | Code: H | nature_of_ownership: BY ISSUER RETIREMENT PLAN | shares_owned_after: 3,761.00
• Sold 2,226 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-19 | Code: M | equity_swap_involved: 0 | shares_owned_after: 2,226.00 | transaction_form_type: 4 | Footnotes: F1, F4, F4, F4

Footnotes:

• F1: Restricted stock units convert into common stock on a one-for-one basis.
• F2: Includes 851 shares of Common Stock purchased pursuant to the Origin Bancorp, Inc. 2021 Employee Stock Purchase Plan ("ESPP"), for the purchase period of June 01, 2025 to May 31, 2026.
• F3: Represents the number of common stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the restricted stock units and does not represent a sale.
• F4: Granted on August 19, 2022, vesting ratably over five years with the first vest date of August 19, 2023.